Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Definium Therapeutics Publishes Healthcare Claims Study on Treatment Patterns in Generalized Anxiety Disorder
8+ hour, 30+ min ago (468+ words) marketscreener.com...
BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
2+ mon, 1+ week ago (534+ words) marketscreener.com BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia Published on 05/28/2026 at 07:51 am EDT BioXcel Therapeutics, Inc. announced the presentation of new positive data from the Phase 3 SERENITY At-Home…...
Minerva Neurosciences: Olanzapine added to Roluperidone, in patients with negative symptoms (NS) of schizophrenia
4+ mon, 1+ week ago (566+ words) Published on 03/26/2026 at 01:57 pm EDT A Study of roluperidone coadministered with olanzapine in patients with negative symptoms (NS) of schizophrenia An open-label safety trial Specific Affinity for 5-HT2A, σ 2, and σ 1-adrenergic receptors The behavioural pharmacology package is consistent with an…...
Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital
4+ mon, 3+ week ago (82+ words) marketscreener.com Biotechnology & Medical Research Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital Published on 03/16/2026 at 08:50 am EDT Latest news about Alzamend Neuro, Inc. Chart…...